Scots choose chewy Lipitor but refuse Zytiga, Sycrest and Gilenya
This article was originally published in Scrip
Executive Summary
Scotland's health technology assessment body, the Scottish Medicines Consortium, has rejected several drugs, including the first MS pill, Novartis' Gilenya and Janssen-Cilag's Zytiga (abiraterone acetate) for prostate cancer, for use on the Scottish NHS because the submitting companies failed to argue an economic case for their drugs.